Literature DB >> 24906688

Reliability and validity of Leicester Cough Questionnaire Korean version.

Jong-Min Han1, In-Chul Jung1, Weechang Kang2, Seung-Su Kim3, Yoon Yeo4, Yang-Chun Park5.   

Abstract

The Leicester Cough Questionnaire (LCQ) is a self-administered questionnaire developed in England and validated for reliability. We developed a Korean translation of this questionnaire by applying a sequential forward and backward translation approach. The purpose of this study is to validate the Korean version of the LCQ (LCQ-K) in Korean patients with chronic cough. A multicenter prospective study was undertaken with 100 chronic cough patients who consented to participate in the study. The LCQ-K includes eight physical items, seven psychological items, and four social items. Visual analog scale (VAS) of cough, Borg Cough Scale (BCS), and Short Form-36 (SF-36) were used as external comparators. Participants included 52 women and 48 men with ages ranging from 18 years to 69 years. The concurrent validity comparing LCQ-K to VAS, BCS, and SF-36 yielded statistically significant Pearson correlation coefficients. The LCQ-K showed good reliability in three domains, with Cronbach's α coefficients ranging from 0.84 to 0.87 (total: 0.91). Test-retest reliability was investigated with single measure intraclass correlation coefficients, which were found to be practically and statistically significant (p = 0.005). Responsiveness was validated by effective size ranging from 1.16 to 1.40 in each domain. LCQ-K is a reliable, valid, and responsive disease-specific questionnaire for assessing symptoms and quality of life of Korean patients with chronic cough.
© The Author(s) 2014.

Entities:  

Keywords:  Chronic cough; Leicester Cough Questionnaire; quality of life; reliability; validity

Year:  2014        PMID: 24906688     DOI: 10.1177/1479972314536206

Source DB:  PubMed          Journal:  Chron Respir Dis        ISSN: 1479-9723            Impact factor:   2.444


  6 in total

1.  Validation of a Spanish version of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis.

Authors:  Gerard Muñoz; Maria Buxó; Javier de Gracia; Casilda Olveira; Miguel Angel Martinez-Garcia; Rosa Giron; Eva Polverino; Antonio Alvarez; Surinder S Birring; Montserrat Vendrell
Journal:  Chron Respir Dis       Date:  2016-02-22       Impact factor: 2.444

2.  Efficacy and safety of Maekmoondong-tang for chronic dry cough: a study protocol for a randomized controlled trial.

Authors:  Kwan-Il Kim; Seungwon Shin; Kyuseok Kim; Junhee Lee
Journal:  BMC Complement Altern Med       Date:  2016-02-02       Impact factor: 3.659

3.  Efficacy and Safety of Ojeok-San Plus Saengmaek-San for Gastroesophageal Reflux-Induced Chronic Cough: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Yee Ran Lyu; Kwan-Il Kim; Changsop Yang; So-Young Jung; O Jin Kwon; Hee-Jae Jung; Jun-Hwan Lee; Beom-Joon Lee
Journal:  Front Pharmacol       Date:  2022-03-01       Impact factor: 5.810

4.  Efficacy and safety of GHX02 in the treatment of acute bronchitis: protocol of a phase II, double-blind, randomised placebo-controlled trial.

Authors:  Yee Ran Lyu; Won-Kyung Yang; So Jung Park; Seung-Hyeong Kim; Wee-Chang Kang; In Chul Jung; Yang Chun Park
Journal:  BMJ Open       Date:  2018-05-14       Impact factor: 2.692

5.  Psychometric properties of the German version of the Leicester Cough Questionnaire in sarcoidosis.

Authors:  Jonas Christian Schupp; Urs Alexander Fichtner; Björn Christian Frye; Katja Heyduck-Weides; Surinder S Birring; Wolfram Windisch; Carl-Peter Criée; Joachim Müller-Quernheim; Erik Farin
Journal:  PLoS One       Date:  2018-10-04       Impact factor: 3.240

6.  Efficacy and Safety of GHX02 in the Treatment of Acute Bronchitis and Acute Exacerbation of Chronic Bronchitis: A Phase Ⅱ, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.

Authors:  Su Won Lee; Yee Ran Lyu; Si Yeon Kim; Won Kyung Yang; Seung Hyung Kim; Ki Mo Kim; Sung-Wook Chae; Weechang Kang; In Chul Jung; Yang Chun Park
Journal:  Front Pharmacol       Date:  2022-01-17       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.